Based on its excellent diagnostic performance, several international PCa guidelines, including the European Association of Urology guideline, recommend PSMA PET/CT for patients with recurrent PSA after primary therapy (2, 8, 9). This evidence concerns the gene FOLH1 and posterior cortical atrophy.